Roche Glycart Ag

Hoffmann-La Roche Inc.

Glycart Biotechnology Ag

Roche Glyeart Ag

F. Hoffmann-La Roche Ag

Pablo Umaña

Christian Klein

Ekkehard Mössner

Ekkehard Moessner

Joël Jean-Mairet

James E Bailey

Ralf Hosse

Anne Freimoser-Grundschober

Thomas U Hofer

Wolfgang Richter

Peter Bruenker

Valeria G Nicolini

Inja Waldhauer

Alexander Bujotzek

Wei Xu

Johannes Sam

Alexander Knaupp

Halina Trochanowska

Tobias Suter

Claudia Ferrara Koller

Stefan Klostermann

Tanja Fauti

Lydia Jasmin Hanisch

Guy Georges

Marina Bacac

Sandra Grau-Richards

Joerg Benz

Maria Amann

Peter Brünker

Ursula Püntener

Ralf Jörg Hosse

Claudia Ferrara

M Sean Bailey, Legal Representative

Stephan Gasser

Maria Valeria Gonzalez Nicolini

Jenny Tosca Thom

Christina Claus

Harald Duerr

Christiane Neumann

Tina Weinzierl

Mario Perro

Christine Trumpfheller

Moritz Rapp

Laurene Pousse

Estelle Marrer-Berger

Alejandro Carpy Gutierrez Cirlos

Teemu Tapani Junttila

Michela Silacci-Melkko

Claudia Ferrera Koller

Mudita Pincha

Jean-Baptiste Vallier

Christine Kuettel

Simon Patrick Keiser

Stephane Leclair

Eva Carina Sum

BISPECIFIC ANTIBODY MOLECULES BINDING TO CD3 AND EGFRvIII

The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to CD3 and CD19

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules capable of specific binding to CD40 and to fap

The present invention generally relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to HLA-A2/WT1

The present invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.

Agonistic CD28 antigen binding molecules targeting Her2

The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to HLA-A2/MAGE-A4

The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists

The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Bispecific antibody molecules binding to CD3 and TYRP-1

The invention relates to bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to epithelial cell adhesion molecule (EpCAM), and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecule for a costimulatory TNF receptor

The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.

Tumor-targeted agonistic CD28 antigen binding molecules

The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Bispecific antibody molecules binding to CD3 and EGFRvIII

The invention relates to novel bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to tenascin C (TnC), and to methods of producing these molecules and to methods of using the same.

The invention relates to new bispecific antigen binding molecules, comprising at least one antigen binding domain capable of specific binding to 4-1BB, at least one moiety capable of specific binding to a target cell antigen, and a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules comprising anti-4-1BB clone 20H4.9

Growing community of inventors

Zurich, Switzerland

Pablo Umaña